Reflecting this, the National Comprehensive Cancer Network’s 2019 guidelines include avelumab (anti-PD-L1), pembrolizumab (anti-PD-1) and nivolumab (anti-PD-1) as preferred therapies for patients with advanced MCC [7]. This evidence concerns the gene CD274 and Merkel cell skin cancer.